CERo Therapeutics Holdings Yönetim

Yönetim kriter kontrolleri 0/4

CERo Therapeutics Holdings CEO'su Chris Ehrlich, Sep2024 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 3.86% doğrudan sahiptir ve bu hisselerin değeri $ 851.92K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 0.1 yıl ve 0.8 yıldır.

Anahtar bilgiler

Chris Ehrlich

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	3.9%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	less than a year

Son yönetim güncellemeleri

Recent updates

CEO

Chris Ehrlich (54 yo)

less than a year

Görev süresi

Mr. Christopher B. Ehrlich, M.B.A. also known as Chris, serves as Chief Executive Officer & Chair of CERo Therapeutics, Inc. Mr. Ehrlich was Director at ProLynx Inc since September 2022 until 2023. He serv...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christopher Ehrlich	CEO & Chair	less than a year	Veri yok	3.86% $ 851.9k
Brian Atwood	President & Director	no data	Veri yok	13.13% $ 2.9m
Lawrence Corey	Co-founder & Head of Scientific Advisory Board	no data	Veri yok	5.62% $ 1.2m
Andrew Kucharchuk	CFO & Director	less than a year	Veri yok	0% $ 0
Kristen Pierce	Chief Development Officer & Director	less than a year	Veri yok	0% $ 0

0.08yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: CERO 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.1 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christopher Ehrlich	CEO & Chair	less than a year	Veri yok	3.86% $ 851.9k
Brian Atwood	President & Director	less than a year	Veri yok	13.13% $ 2.9m
Lawrence Corey	Co-founder & Head of Scientific Advisory Board	no data	Veri yok	5.62% $ 1.2m
Andrew Kucharchuk	CFO & Director	less than a year	Veri yok	0% $ 0
Kristen Pierce	Chief Development Officer & Director	less than a year	Veri yok	0% $ 0
Kathleen LaPorte	Independent Director	less than a year	Veri yok	0.65% $ 142.9k
Shami Patel	Independent Director	less than a year	Veri yok	Veri yok
Adrian Bot	Scientific Advisor	no data	Veri yok	Veri yok
Antonio Lanzavecchia	Scientific Advisor	no data	Veri yok	Veri yok
Rafi Ahmed	Scientific Advisor	no data	Veri yok	Veri yok
Michael Byrnes	Independent Director	less than a year	Veri yok	0% $ 0
Lindsey Rolfe	Independent Director	less than a year	Veri yok	0% $ 0

0.8yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CERO 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 0.8 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

CERo Therapeutics Holdings Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

CERo Therapeutics Holdings, Inc. Appoints Shami Patel to the Board as Class III Director

CERo Therapeutics Holdings, Inc. Appoints Andrew Albert Kucharchuk as Chief Financial Officer

High number of new and inexperienced directors

Recent updates

CERo Announces Reverse Stock Split to Regain Compliance with the Bid Price Requirement

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

CERo Therapeutics Holdings, Inc. announced delayed 10-Q filing

Nasdaq Determines to Delist CERo Therapeutics Holdings' Securities from The Nasdaq Global Market on November 8, 2024 Due to Failure to Regain Compliance with the MVLS Requirement within the Cure Period

CERo Therapeutics Holdings Receives Low Price Deficiency Letter from Nasdaq and Nasdaq Determines to Delist its Securities from The Nasdaq Global Market

CERo Therapeutics Holdings, Inc. Announces Submission of IND Clinical Hold Complete Response Letter

CERo Therapeutics Holdings, Inc. Appoints Shami Patel to the Board as Class III Director

CERo Therapeutics Holdings, Inc. Appoints Andrew Albert Kucharchuk as Chief Financial Officer

CERo Therapeutics Holdings, Inc. announced that it expects to receive $1.2 million in funding

CERo Therapeutics Holdings, Inc. announced that it expects to receive $1.25 million in funding

CERo Therapeutics Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement and MVPHS Requirement

CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236

CERo Therapeutics Holdings, Inc. announced delayed 10-Q filing

CERo Therapeutics Holdings Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum $50 Million Market Value of Listed Securities Requirement Set Forth in Nasdaq Listing Rule 5450(b)(2)(A)

CERo Therapeutics Holdings, Inc. announced delayed annual 10-K filing

CERo Therapeutics Holdings, Inc. announced delayed annual 10-K filing

New major risk - Shareholder dilution

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of its Clinical Candidate CER-1236 to Treat AML Patients

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of its Clinical Candidate CER-1236 to Treat AML Patients

Phoenix Biotech Acquisition Corp.(NasdaqGM:CERO) dropped from NASDAQ Composite Index

CERo Therapeutics Holdings, Inc. announced that it has received $9.4 million in funding

New minor risk - Share price stability

Phoenix Biotech Acquisition Corp. announced that it expects to receive $2 million in funding from Keystone Capital Partners LLC

High number of new and inexperienced directors

Phoenix Biotech Acquisition Corp. Receives Non-Compliance Letter from Nasdaq related to Listing Rule 5450(a)(2

Phoenix Biotech Acquisition Corp. Receives Non-Compliance Letter from Nasdaq related to Listing Rule 5450(a)(2

CERo Therapeutics, Inc. entered into a definitive business combination agreement to acquire Phoenix Biotech Acquisition Corp. (NasdaqGM : PBAX) in a reverse merger transaction for an implied enterprise value of approximately $110 million.

Phoenix Biotech Acquisition Corp. (NasdaqGM:PBAX) entered into a business combination agreement to acquire Intrinsic Medicine, Inc. for approximately $140 million.

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş